Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

Cath Lab Teams Find Enduring Lessons in COVID-19’s Unending Reign

News Features

Cath Lab Teams Find Enduring Lessons in COVID-19’s Unending Reign

December 20, 2021

Discharge Safe as Early as a Day After Primary PCI for STEMI

News Daily News

Discharge Safe as Early as a Day After Primary PCI for STEMI

December 15, 2021

Smartphone App Hears Speech Changes Indicating Fluid Buildup in HF

News Daily News

Smartphone App Hears Speech Changes Indicating Fluid Buildup in HF

December 10, 2021

Statins Underprescribed in PAD Before and After Interventions

News Daily News

Statins Underprescribed in PAD Before and After Interventions

December 03, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

COVID-19: TCTMD’s Dispatch for November Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 3

November 15, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

ACC Survey Reveals Racial/Ethnic Gaps but Also Job Satisfaction

News Daily News

ACC Survey Reveals Racial/Ethnic Gaps but Also Job Satisfaction

October 18, 2021

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HF Care Didn’t Suffer as Clinicians Turned to Telehealth in COVID-19

News Daily News

HF Care Didn’t Suffer as Clinicians Turned to Telehealth in COVID-19

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

October 06, 2021

VALVENOR Study Helps Clarify Risks in Moderate AS Patients

News Daily News

VALVENOR Study Helps Clarify Risks in Moderate AS Patients

October 01, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

News Daily News

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

Michael O'Riordan

September 27, 2021

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

CMS Pays More to Male Cardiologists, but the Reasons Why Are Murky

News Daily News

CMS Pays More to Male Cardiologists, but the Reasons Why Are Murky

Michael O'Riordan

September 10, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.